About Arzeda
Arzeda is a Healthcare company based in Seattle (United States) founded in 2008 by Eric Althoff, David Baker, Daniela Grabs-Rothlisberger, and Alexandre Zanghellini. It operates as a synthetic enzymes are designed using computational technology for industrial applications. Arzeda has raised $94.96 million across 21 funding rounds from investors including W. L. Gore & Associates, United States Department of Agriculture and Bunge. The company has 66 employees. Its chief executive is Alexandre Zanghellini. Arzeda offers products and services including Intelligent Protein Design Technology and Reb M. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Proteomics. Its legal entity is ARZEDA CORP. Its competitors include Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Arzeda was founded in 2008 in Seattle, United States, within the biotechnology sector. Computational enzyme design and protein optimization are integrated with metabolic bioengineering to produce novel synthetic enzymes. Designer cell factories are engineered for large-scale chemical manufacturing. Operations focus on bridging gaps in enzyme functionality through targeted innovations, supporting industrial processes in sustainable production.
- Headquarters Seattle, United States
- Employees 66
- Founders Eric Althoff, David Baker, Daniela Grabs-Rothlisberger, Alexandre Zanghellini
- SectorsHealthcare
- Website arzeda.com
- Social LinkedIn X
- Legal Name Arzeda Corp
- Total Equity Funding$94.96M (USD)
in 21 rounds
- Latest Funding Round$4.51M (USD), Series B
Aug 2025
- InvestorsW. L. Gore & Associates
& 19 more
- Employee Count66
Products & Services of Arzeda
Arzeda offers a comprehensive portfolio of products and services, including Intelligent Protein Design Technology and Reb M.
AI tool for creating new proteins and enzymes for sustainability
Cost-effective stevia alternative for better taste in food industry
Funding Insights of Arzeda
Arzeda has successfully raised a total of $94.96M across 21 strategic funding rounds. The most recent funding activity was a Series B round of $4.51 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $94.96M
- Total Rounds 21
- Last Round Series B — $4.51M
- First Round $149,237
(Nov 2009)
- Investors Count 20
Latest 10 of 21 funding rounds of Arzeda with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2025 | $4.51M | Series B | – | – | – |
| Oct 2023 | $38M | Series B | – | – | |
| Mar 2022 | $33M | Series B | – | Conti Ventures | |
| Sep 2021 | $1.5M | Grant | – | – | |
| Nov 2020 | $3.25M | Series B | – | – | – |
| Nov 2019 | $1M | Series A | – | – | – |
| Nov 2017 | $3.2M | Series A | – | – | |
| Jul 2017 | $12M | Series A | – | OS Fund | |
| Mar 2015 | $1.26M | Grant | – | – | |
| Feb 2015 | $1.26M | Grant | – | – |
20 investors in total: 20 institutional.
Investors in Arzeda
Arzeda has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include W. L. Gore & Associates, United States Department of Agriculture and Bunge.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sofinnova Partners is focused on life sciences and healthcare investments. | – | sofinnovapartners.com | Paris, France | |
VC firm that does early stage investments in the US | – | fall-line-capital.com | San Mateo, United States | |
Venture capital investments are directed toward agriculture and food sectors. | – | lewisandclarkagrifood.com | St. Louis, United States | |
Investments are directed to food, agribusiness, and commodities sectors. | – | continentalgrain.com | New York, United States | |
- | – | contiventures.tcc.mode | - | |
Investment management focused on circular economy and plastic supply chains in high-growth markets. | 2017 | circulatecapital.com | - | |
Early-stage centric sector-agnostic VC firm investing in geographies such as the US | – | osfund.co | Chicago, United States | |
Investing in Life Sciences sectors like Healthcare and Biotechnology. | – | casdincapital.com | - | |
Tech & Life sciences focused VC firm investing primarily in Japan | – | umi.co.jp | Tokyo, Japan | |
- | – | bioeconomycapital.com | - |
Investor details for Arzeda
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Arzeda
29 people are tracked at Arzeda (14 in leadership, 15 in team); the tracked headcount is 66.
| Name | Role | Group |
|---|---|---|
Eric Althoff | Co-Founder | Leadership |
David Baker | Co-Founder | Leadership |
Daniela Grabs-Rothlisberger | Co-Founder | Leadership |
Alexandre Zanghellini | Co-Founder & CEO | Leadership |
Daniela Grabs | Co-Founder & VP, Strategic Projects | Leadership |
Sanjay Pal | CFO | Leadership |
Alex Patist | COO | Leadership |
Ken Barrett | Chief Business Officer | Leadership |
Cara Tracewell | Director of Assay Development | Leadership |
Jacob Bale | Director, Protein Design | Leadership |
Marthah De Lorme | Associate Director of Bioprocessing | Leadership |
Rudesh Toofanny | Principal Scientist, Head Of Employee Engagement | Leadership |
Sean Sleight | Director | Leadership |
Puvin Pichai | Senior Director, DSP | Leadership |
Jacob Herman | Engineer II | Team |
Carlie Parrish | Engineer 2 | Team |
Jagveer Singh | Senior Software Engineer | Team |
Prajakta Jadhav | Scientist-I, Strain Design | Team |
Simon Diez | Scientist Ii, Genetic Design And Build | Team |
Parker Sommerville, PhD | Business Development Analyst | Team |
9 more people are available in the full profile.
Complete people profiles for Arzeda
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Arzeda
3 dated milestones of Arzeda across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Arzeda is founded.
- Funding First funding round of $149K.
- Funding Latest funding round, Series B, of $4.5M.
Competitors of Arzeda
Arzeda has 9 listed competitors in our database, 9 of them funded. They include Somalogic, Nautilus Biotechnology, Amunix, Biognosys and Elektrofi, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| somalogic.com | 1999 | Boulder, United States | $663.99M | 319 | Protein-based assays are developed for life science research. | |
| nautilus.bio | 2016 | Seattle, United States | $103.26M | 134 | A proteomics platform is developed for analyzing the human proteome. | |
| amunix.com | 2006 | Mountain View, United States | $200.59M | 82 | Peptide-based therapeutics are developed for cancers and immune disorders. | |
| biognosys.com | 2008 | Schlieren, Switzerland | $9.13M | – | Proteomics services are delivered via discovery and targeted platforms. | |
| elektrofi.com | 2016 | Boston, United States | $152.25M | 71 | Digital platform transforming the delivery of biologic medicines | |
| proteinsimple.com | 2004 | San Jose, United States | $114.29M | 157 | Provider tools to help researchers with protein analysis | |
| aalphabio.com | 2017 | Seattle, United States | $45.24M | 48 | Developer of cell-based tool for the measurements of protein interactions | |
| glyphic.bio | 2021 | San Francisco, United States | $39.2M | 26 | Next-generation protein sequencing platform is developed for proteome analysis. | |
| dynamic-biosensors.com | 2011 | Planegg, Germany | $5.83M | 51 | Label-free solutions for molecular interactions and biophysical analysis are provided. |
Detailed competitors of Arzeda
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Arzeda
The website of Arzeda (arzeda.com) receives about 3.4K visits a month.
- Monthly visits3.4K
▼ 13.9% vs previous month
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as Arzeda (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Arzeda
Complete news archive for Arzeda
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arzeda
Arzeda was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Arzeda is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Alexandre Zanghellini is the current CEO of Arzeda. They have also founded this company.
Arzeda is a funded company, having raised a total of $94.96M across 21 funding rounds to date. The company's 1st funding round was a Grant of $1.26M, raised on Nov 2009.
Arzeda has 66 employees.
Arzeda was founded in 2008 in Seattle, United States, within the biotechnology sector. Computational enzyme design and protein optimization are integrated with metabolic bioengineering to produce novel synthetic enzymes. Designer cell factories are engineered for large-scale chemical manufacturing. Operations focus on bridging gaps in enzyme functionality through targeted innovations, supporting industrial processes in sustainable production.
Arzeda's top competitors include Somalogic, Nautilus Biotechnology and Elektrofi.
Arzeda offers Intelligent Protein Design Technology and Reb M.
Arzeda has 20 investors. Key investors include W. L. Gore & Associates, United States Department of Agriculture, Bunge, Sofinnova Partners, and Fall Line Capital.
Arzeda operates through Arzeda Corp.